Indivior Pharmaceuticals, Inc 6-K, filed Jan 28, 2025
Indivior Pharmaceuticals, Inc. (INDV)
6-K
2025-01-28
For: 2025-01-28
View Original
Added on
July 07, 2026
About this 6-K
Indivior Pharmaceuticals, Inc filed this 6-K on January 28, 2025.
|
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
________________________
Washington, D.C. 20549
_____________________
FORM 6-K
_____________________
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of January 2025
Commission File Number: 001-37835
________________________________________
Indivior PLC
________________________________________
10710 Midlothian Turnpike, Suite 125
North Chesterfield, Virginia 23235
(Address of principal executive office)
_______________________________
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F
Form
20-F ☒ Form 40-F ☐
|
|
EXHIBIT INDEX
|
Exhibit
No.
|
Description
of Exhibit
|
|
99.1
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
Indivior PLC
|
|
Date: January 28, 2025
|
/s/
Kathryn Hudson
|
|
|
Name:
Kathryn Hudson
|
|
|
Title:
Company Secretary
|
Exhibit
99.1
TR-1: Standard form for notification of major holdings
1. Issuer Details
ISIN
|
GB00BN4HT335
|
Issuer Name
|
INDIVIOR PLC
|
UK or Non-UK Issuer
|
UK
|
2. Reason for Notification
|
An acquisition or disposal of voting rights; Other
|
Comments
|
Application of Trading Book Exemption (see Section 11
below)
|
3. Details of person subject to the notification
obligation
Name
|
Morgan Stanley
|
City of registered office (if applicable)
|
|
Country of registered office (if applicable)
|
US
|
|
Name
|
City
of registered office
|
Country
of registered office
|
|
Morgan
Stanley
|
Wilmington,
Delaware
|
USA
|
4. Details of the shareholder
Full name of shareholder(s) if different from the person(s) subject
to the notification obligation, above
|
|
City of registered office (if applicable)
|
|
Country of registered office (if applicable)
|
|
5. Date on which the threshold was crossed or reached
|
23-Jan-2025
|
6. Date on which Issuer notified
|
27-Jan-2025
|
7. Total positions of person(s) subject to the notification
obligation
|
|
% of voting rights attached to shares (total of 8.A)
|
% of voting rights through financial instruments (total of 8.B 1 +
8.B 2)
|
Total of both in % (8.A + 8.B)
|
Total number of voting rights held in issuer
|
|
Resulting
situation on the date on which threshold was crossed or
reached
|
0.000000
|
0.000000
|
0.000000
|
0
|
|
Position
of previous notification (if applicable)
|
3.512521
|
1.588316
|
5.100837
|
|
8. Notified details of the resulting situation on the date on which
the threshold was crossed or reached
8A. Voting rights attached to shares
|
Class/Type of shares ISIN code(if possible)
|
Number of direct voting rights (DTR5.1)
|
Number of indirect voting rights (DTR5.2.1)
|
% of direct voting rights (DTR5.1)
|
% of indirect voting rights (DTR5.2.1)
|
|
GB00BN4HT335
|
|
0
|
|
0.000000
|
|
Sub
Total 8.A
|
0
|
0.000000%
|
||
8B1. Financial Instruments according to (DTR5.3.1R.(1)
(a))
|
Type of financial instrument
|
Expiration date
|
Exercise/conversion period
|
Number of voting rights that may be acquired if the instrument is
exercised/converted
|
% of voting rights
|
|
|
|
|
|
|
|
Sub
Total 8.B1
|
|
|
|
|
8B2. Financial Instruments with similar economic effect according
to (DTR5.3.1R.(1) (b))
|
Type of financial instrument
|
Expiration date
|
Exercise/conversion period
|
Physical or cash settlement
|
Number of voting rights
|
% of voting rights
|
|
|
|
|
|
|
|
|
Sub
Total 8.B2
|
|
|
|
||
9. Information in relation to the person subject to the
notification obligation
|
2.
Full chain of controlled undertakings through which the voting
rights and/or the financial instruments are effectively held
starting with the ultimate controlling natural person or legal
entities (please add additional rows as
necessary)
|
|
Ultimate controlling person
|
Name of controlled undertaking
|
% of voting rights if it equals or is higher than the notifiable
threshold
|
% of voting rights through financial instruments if it equals or is
higher than the notifiable threshold
|
Total of both if it equals or is higher than the notifiable
threshold
|
|
Morgan
Stanley (Chain 1)
|
|
|
|
|
|
Morgan
Stanley (Chain 1)
|
Morgan
Stanley Capital Management, LLC
|
|
|
|
|
Morgan
Stanley (Chain 1)
|
Morgan
Stanley Smith Barney LLC
|
|
|
|
10. In case of proxy voting
Name of the proxy holder
|
|
The number and % of voting rights held
|
|
The date until which the voting rights will be held
|
|
11. Additional Information
|
The notification was triggered due to Morgan Stanley's total
applicable holding dropping below 5%. As a result, Morgan Stanley
has applied the trading book exemption (DTR 5.1.3R(4)) to its
remaining applicable holding of 4.96% as of January 23,
2025.
|
12.
Date of Completion
|
27-Jan-2025
|
13. Place Of Completion
|
Mumbai
|